Replimune Group Stock (NASDAQ:REPL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$12.34

52W Range

$4.92 - $17.00

50D Avg

$12.22

200D Avg

$9.61

Market Cap

$941.76M

Avg Vol (3M)

$821.11K

Beta

1.19

Div Yield

-

REPL Company Profile


Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

331

IPO Date

Jul 20, 2018

Website

REPL Performance


REPL Financial Summary


Mar 24Mar 23Mar 22
Revenue---
Operating Income$-236.69M$-177.08M$-118.31M
Net Income$-215.79M$-174.28M$-118.04M
EBITDA$-234.04M$-177.40M$-114.06M
Basic EPS$-3.24$-2.99$-2.26
Diluted EPS$-3.24$-2.99$-2.26

Fiscal year ends in Mar 24 | Currency in USD

Peer Comparison


TickerCompany
MRUSMerus N.V.
AVTEAerovate Therapeutics, Inc.
NUVLNuvalent, Inc.
KRONKronos Bio, Inc.
GOSSGossamer Bio, Inc.
PRTCPureTech Health plc
KROSKeros Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
ASNDAscendis Pharma A/S
SNDXSyndax Pharmaceuticals, Inc.
UTHRUnited Therapeutics Corporation
PTGXProtagonist Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.
NAMSNewAmsterdam Pharma Company N.V.
KURAKura Oncology, Inc.
LYRALyra Therapeutics, Inc.